UNSPSC 51383304: Diclofenac

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H11Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 144O8QL0L1, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but generally known as diclofenac, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07092MIG.

UNSPSC 51383304 Diclofenac, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities record solicitations for naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and OTC products — none of which involve diclofenac or the specific nonsteroidal anti-inflammatory drug market the code nominally describes. The mismatch suggests either a data-tagging error in the source or a broader pharmaceutical-procurement category being imprecisely coded at the commodity level. State and local activity under this code shows little relevant recent momentum for diclofenac specifically.

The issuing bodies reflect a mix of county health departments, state health commissions, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (note: the posting date of June 30, 2026 appears inconsistent with the 2023 deadline and suggests a data quality issue in the source). The Texas Health and Human Services Commission posted an RFI on therapeutic pharmacy initiative direct-to-manufacturer prescriptions with a response deadline of April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, released an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, serving participating state and local facilities across Minnesota and Oregon. Without recent opportunities specifically for diclofenac or closely related products, the code presents limited visibility into current demand signals for business development targeting state and local pharmaceutical procurement.